FeesSafety
Pluang+

ProShares UltraShort Bloomberg Crude Oil ETF lost ~99.5% over 10 years, risky but may offer tactical entry.

Market News
14 Sep 2026
Seeking Alpha
View Source
Neutral
ProShares UltraShort Bloomberg Crude Oil ETF lost ~99.5% over 10 years, risky but may offer tactical entry.

The ProShares UltraShort Bloomberg Crude Oil ETF (SCO) provides -2x daily inverse exposure to WTI crude oil but has lost about 99.5% of its value over the past decade due to extreme volatility and a high expense ratio of 0.95%. It is generally unsuitable for most investors because of poor long-term performance but could present a tactical opportunity amid ongoing geopolitical tensions, especially involving Iran and the Strait of Hormuz, which keep oil prices elevated. The analyst is monitoring the period around December 2026 to January 2027 for a potential entry point, contingent on signs of global oil inventories stabilizing and rebalancing.

More News

Dayton T. Brown opens new Huntsville Test & Qualification Center to boost aerospace and defense testing.

Dayton T. Brown opens new Huntsville Test & Qualification Center to boost aerospace and defense testing.

Dayton T. Brown, Inc. inaugurated its new 104,000-square-foot Test & Qualification Center in Huntsville, Alabama, enhancing its capacity to support aerospace, defense, and propulsion programs. The facility's strategic location near Huntsville's aeros...

Market News
Bullish
1 hour ago
60% of CCOs say communications functions lag behind their leadership roles, needing better systems and resources.

60% of CCOs say communications functions lag behind their leadership roles, needing better systems and resources.

A new study by The Grossman Group reveals that while 60% of chief communications officers (CCOs) have influence at the leadership level, their communications functions lack the necessary systems, skills, and AI capabilities to fully meet their mandat...

Others
Neutral
1 hour ago
Over 200 companies advance 240+ Alzheimer's drugs, marking a new phase in treatment development

Over 200 companies advance 240+ Alzheimer's drugs, marking a new phase in treatment development

More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...

Market News
Bullish
1 hour ago
Sagimet Biosciences starts key Phase 3 trial for acne drug denifanstat in the U.S.

Sagimet Biosciences starts key Phase 3 trial for acne drug denifanstat in the U.S.

Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to support regula...

Market News
Bullish
1 hour ago
Nokia beats Q3 earnings and revenue estimates with strong AI and cloud sales growth.

Nokia beats Q3 earnings and revenue estimates with strong AI and cloud sales growth.

Nokia reported third-quarter 2026 earnings per share of $0.10, surpassing the $0.08 estimate, and revenue of $5.78 billion, exceeding the $5.72 billion forecast. The company's AI and cloud sales surged 123%, driven by high demand for its IP Networks ...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App